ARV-110 is an orally bioavailable CRBN degrader targeting AR (androgen receptor) and developed by Arvinas, Inc. Its efficacy was demonstrated both in vitro (DC50 around 1 nM in all tested prostatic cancer cell lines) and in vivo, where it significantly inhibited the growth of enzalutamide-insensitive tumours [43]. The gene discussed is AR; the disease is neoplasm.